FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570504112> ?p ?o ?g. }

• W1570504112 endingPage "404" @default.
• W1570504112 startingPage "401" @default.
• W1570504112 abstract "Owing to the lack of biologically based clinical measures and reliable biomarkers for many indications within the CNS area, the use of imaging tools, such as ligand-based positron emission tomography (PET), has become more and more important in the development of new CNS drugs. A well-grounded and reliable relationship between the plasma concentration of the drug and the occupancy of the receptor/transporter is a powerful tool to investigate the mechanism of action of a new drug and to guide dose selection in patients. Imaging of the serotonin transporter (5-HTT) by means of either PET or single photon emission computed tomography (SPECT) is one of the most useful methods in the neuro- and psychopharmacological field. A number of different ligands have been tested and used over the past 20 years. The first radiotracer ligand to be used in human beings was the SPECT ligand [123I]2-β-carbomethoxy-3-β-(4-iodophenyl)-tropane (β-CIT), and in 1995, the first successful PET imaging study of the distribution of the 5-HTT in the brain of human volunteers using [11C](+)McN5652 (trans-1,2,3,5,6,10-β-hexahydro-6-[4-(methylthio)phenyl]-pyrrolo-[2,1-a]-isoquioline) was reported [1]. In 2005, the first study with the PET ligand [11C]-MADAM (N,N-dimethyl-2-(2-amino-4-methylphenylthio) benzylamine) in human beings was reported [2], and the suitability of the cerebellum as a reference region for non-specific [11C]-MADAM binding could be confirmed, thus paving the way for experimentally less demanding approaches, such as the simplified reference tissue model. The ligand [11C]-DASB (3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile) seems today to be the most widely used, because of its selectivity, reversibility, reliability and great specific binding [3]. A thorough review of different 5-HTT ligands has been given by Meyer [4]. A summary of the characteristics for [11C]-MADAM and [11C]-DASB is given in table 1. Lu AA21004 (1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine) is a novel compound currently in phase III testing as an antidepressant [5]. In recombinant cell lines, the multimodal antidepressant Lu AA21004 is a 5-HT3 and 5-HT7 receptor antagonist, 5-HT1A receptor agonist, 5-HT1B receptor partial agonist and inhibitor of the 5-HTT. In non-clinical studies, Lu AA21004 increases levels of noradrenaline, dopamine, acetylcholine and histamine [6]. The affinities for the 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 receptors and the 5-HTT are all considered to be of clinical relevance and involved in the mechanism of action at therapeutic doses. In contrast to selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenalin reuptake inhibitors (SNRIs), which mainly have affinity for the 5-HTT [and noradrenalin transporter (NAT) in case of SNRIs], Lu AA21004 has a broad receptor-binding profile. During the clinical development of Lu AA21004, two PET studies have been performed using 5-HTT ligands (either [11C]-MADAM or [11C]-DASB) to quantify the 5-HTT occupancy in the brain of human subjects. The purpose of this study was to describe the 5-HTT human brain occupancy after Lu AA21004 administration and its relation to the plasma concentrations of Lu AA21004. Study designs. Data originate from two different open-label studies, performed at different sites (necessary because of subject recruitment) and with access to different 5-HTT ligands. In study A, PET measurements were taken on day 1 (i.e. after a single dose) and on day 9 of multiple dosing in 11 young healthy Caucasian subjects using the [11C]-MADAM ligand. In study B, PET measurements were taken after 13 days of multiple dosing in 35 young healthy Caucasian or Japanese subjects with the [11C]-DASB ligand. Study A investigated the 5-HTT occupancy at three dose levels of Lu AA21004 (2.5, 10 and 60 mg/day), whereas the doses in study B were 2.5, 5 and 20 mg/day. Both studies were approved by local ethics committees and were conducted in accordance with Good Clinical Practice (GCP) and the Declaration of Helsinki. The data set consisted of 46 healthy male subjects (28 Caucasian and 18 Japanese) with a mean age of 28 years (range, 21–41). The mean weight and BMI were 73 kg (range, 57–95) and 23 kg/m2 (range, 19–29), respectively. Subjects were enroled after they signed the informed consent form, and it was verified that subjects fulfilled the inclusion criteria and did not meet any exclusion criteria. Pharmacokinetic blood sampling. For study A, venous blood samples (2 mL) for the analysis of plasma content of Lu AA21004 were drawn on day 1 at 1, 2, 3, 4 and 6 hr post-dose; on days 2–8 at pre-dose; and on day 9 at 1, 2, 3, 4, 6, 7, 7.5, 8, 8.5, 9, 9.5, 10, 12, 14, 24, 36, 48, 72, 96 and 120 hr post-dose. For study B, samples were drawn on day 1 at 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hr post-dose, on days 3, 5, 7, 9, 11 and 13 at pre-dose and on day 14 at 1, 2, 3, 4, 6, 7, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hr post-dose. The plasma concentrations of Lu AA21004 were determined using an analytical method validated in accordance with FDA guidance [7]. Lu AA21004 was extracted from plasma followed by liquid chromatography and quantified by a mass spectrometry. The BP at baseline for [11C]-MADAM had a mean (±S.D.) of 4.3 ± 1.7 and hence a coefficient of variation of 40%. For [11C]-DASB, the BP at baseline had a mean (±S.D.) of 2.2 ± 0.39 and a coefficient of variation of 18%. The 5-HTT occupancies at different dosing regimens of Lu AA21004 administration (single or multiple doses) are shown in table 2. The non-linear regression analysis relating plasma concentrations of Lu AA21004 and 5-HTT occupancy using the Emax model gave parameter values of 99% for Emax and 4.8 ng/mL for EC50. The relative standard errors (standard error divided by mean value) were 3.8% and 17%, respectively. The nature of the PET ligand had no significant impact on Emax or EC50, because the decrease in the objective function values was smaller than 7.88 for both ligands. This can also be observed in fig. 1, where the individual curve fits for two ligands are very close to each other. Likewise, race (Caucasian/Japanese) had no significant impact on Emax or EC50. In fig. 1, the plasma concentrations of Lu AA21004 are plotted against the 5-HTT occupancy values. The relationship between Lu AA21004 plasma concentration and 5-HTT occupancy. The plasma concentration of Lu AA21004 versus the observed (circles and triangles) and the estimated curve fits of the 5-HTT occupancy in the raphe nuclei region. The 95% confidence limits of the fitted curve are shown as dotted lines. Filled circles show single-dose data, while open circles and triangles show multiple-dose data. The mean BPs at baseline were 4.3 and 2.2 for [11C]-MADAM and [11C]-DASB, respectively. However, there were no significant differences in the Lu AA21004 plasma concentration-5-HTT occupancy relationship between two ligands. Neither Emax nor EC50 was influenced by which PET ligand had been used. This is consistent with a study by Elfving et al. [9], showing that the DASB and MADAM ligands had similar affinity for 5-HTT in rat and monkey brains. MADAM and DASB displayed significant specific binding to 5-HTT in monkey cerebellum, with receptor density (Bmax) cortex/cerebellum ratios of 3 and 4 for MADAM and DASB, respectively. In rat brain, the Bmax cortex/cerebellum ratios were 6 and 3 with MADAM and DASB, respectively [6]. It has been proposed that the occupancy of the 5-HTT should be around 80% for a conventional SSRI/SNRI to be therapeutically useful [4]. Lu AA21004 has been shown to be efficacious at doses of 5 and 10 mg/day in a clinical phase II proof-of-concept study in patients with major depressive disorder [10]. The plasma concentrations of Lu AA21004 at steady state for 5 mg correspond, using the relation between Lu AA21004 exposure and 5-HTT occupancy, to the 5-HTT occupancy of approximately 50%. This indicates that Lu AA21004 may be efficacious at lower 5-HTT occupancy than necessary with SSRI/SNRIs. The explanation for this may be Lu AA21004’s multimodal neurotransmitter enhancer profile, where the affinity for the receptor subtypes 5-HT1A, 5-HT1B, 5-HT3 and 5-HT7 can contribute to the clinical effect. In conclusion, we have shown that Lu AA21004 occupies the 5-HTT and that the relationship between plasma exposure of Lu AA21004 and 5-HTT occupancy can be reliably described by an Emax model. All authors are employed by H. Lundbeck A/S, the sponsor of two studies. The authors have nothing to disclose." @default.
• W1570504112 created "2016-06-24" @default.
• W1570504112 creator A5016750387 @default.
• W1570504112 creator A5053796772 @default.
• W1570504112 creator A5065833263 @default.
• W1570504112 creator A5070045203 @default.
• W1570504112 date "2011-11-04" @default.
• W1570504112 modified "2023-09-30" @default.
• W1570504112 title "Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects" @default.
• W1570504112 cites W1983638695 @default.
• W1570504112 cites W1998564307 @default.
• W1570504112 cites W2013861319 @default.
• W1570504112 cites W2036812642 @default.
• W1570504112 cites W2037293854 @default.
• W1570504112 cites W2048462359 @default.
• W1570504112 cites W2087102130 @default.
• W1570504112 cites W2125228745 @default.
• W1570504112 cites W2134456636 @default.
• W1570504112 doi "https://doi.org/10.1111/j.1742-7843.2011.00810.x" @default.
• W1570504112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21985522" @default.
• W1570504112 hasPublicationYear "2011" @default.
• W1570504112 type Work @default.
• W1570504112 sameAs 1570504112 @default.
• W1570504112 citedByCount "61" @default.
• W1570504112 countsByYear W15705041122012 @default.
• W1570504112 countsByYear W15705041122013 @default.
• W1570504112 countsByYear W15705041122014 @default.
• W1570504112 countsByYear W15705041122015 @default.
• W1570504112 countsByYear W15705041122016 @default.
• W1570504112 countsByYear W15705041122017 @default.
• W1570504112 countsByYear W15705041122018 @default.
• W1570504112 countsByYear W15705041122019 @default.
• W1570504112 countsByYear W15705041122020 @default.
• W1570504112 countsByYear W15705041122021 @default.
• W1570504112 countsByYear W15705041122022 @default.
• W1570504112 countsByYear W15705041122023 @default.
• W1570504112 crossrefType "journal-article" @default.
• W1570504112 hasAuthorship W1570504112A5016750387 @default.
• W1570504112 hasAuthorship W1570504112A5053796772 @default.
• W1570504112 hasAuthorship W1570504112A5065833263 @default.
• W1570504112 hasAuthorship W1570504112A5070045203 @default.
• W1570504112 hasConcept C126322002 @default.
• W1570504112 hasConcept C134018914 @default.
• W1570504112 hasConcept C160331591 @default.
• W1570504112 hasConcept C170493617 @default.
• W1570504112 hasConcept C185592680 @default.
• W1570504112 hasConcept C18903297 @default.
• W1570504112 hasConcept C2775864247 @default.
• W1570504112 hasConcept C2778897192 @default.
• W1570504112 hasConcept C3017575891 @default.
• W1570504112 hasConcept C3020079912 @default.
• W1570504112 hasConcept C71924100 @default.
• W1570504112 hasConcept C86803240 @default.
• W1570504112 hasConcept C98274493 @default.
• W1570504112 hasConceptScore W1570504112C126322002 @default.
• W1570504112 hasConceptScore W1570504112C134018914 @default.
• W1570504112 hasConceptScore W1570504112C160331591 @default.
• W1570504112 hasConceptScore W1570504112C170493617 @default.
• W1570504112 hasConceptScore W1570504112C185592680 @default.
• W1570504112 hasConceptScore W1570504112C18903297 @default.
• W1570504112 hasConceptScore W1570504112C2775864247 @default.
• W1570504112 hasConceptScore W1570504112C2778897192 @default.
• W1570504112 hasConceptScore W1570504112C3017575891 @default.
• W1570504112 hasConceptScore W1570504112C3020079912 @default.
• W1570504112 hasConceptScore W1570504112C71924100 @default.
• W1570504112 hasConceptScore W1570504112C86803240 @default.
• W1570504112 hasConceptScore W1570504112C98274493 @default.
• W1570504112 hasIssue "4" @default.
• W1570504112 hasLocation W15705041121 @default.
• W1570504112 hasLocation W15705041122 @default.
• W1570504112 hasOpenAccess W1570504112 @default.
• W1570504112 hasPrimaryLocation W15705041121 @default.
• W1570504112 hasRelatedWork W1522849455 @default.
• W1570504112 hasRelatedWork W1971453675 @default.
• W1570504112 hasRelatedWork W2006494840 @default.
• W1570504112 hasRelatedWork W2027622212 @default.
• W1570504112 hasRelatedWork W2050311658 @default.
• W1570504112 hasRelatedWork W2055572014 @default.
• W1570504112 hasRelatedWork W2107899720 @default.
• W1570504112 hasRelatedWork W2128286595 @default.
• W1570504112 hasRelatedWork W2748952813 @default.
• W1570504112 hasRelatedWork W4241062279 @default.
• W1570504112 hasVolume "110" @default.
• W1570504112 isParatext "false" @default.
• W1570504112 isRetracted "false" @default.
• W1570504112 magId "1570504112" @default.
• W1570504112 workType "article" @default.